In:
Science Translational Medicine, American Association for the Advancement of Science (AAAS), Vol. 15, No. 689 ( 2023-03-29)
Abstract:
The survival rate for patients with B cell lymphoblastic leukemia (B-ALL) is quite low in refractory or relapsed pediatric and adult patients. Ten-eleven translocation 1 (TET1) is often overexpressed in this cancer and represents a potential target. Here, Chen et al . saw that overexpression of TET1 was sufficient to transform normal precursor B cells. In addition, the authors targeted ATM or PKC, protein kinases that stabilize TET1, which inhibited B-ALL progression in vivo and when combined with vincristine improved survival in PDX models. The authors demonstrated TET1 as a key regulator of B-ALL and a potential target for treatment that requires further exploration. —DH
Type of Medium:
Online Resource
ISSN:
1946-6234
,
1946-6242
DOI:
10.1126/scitranslmed.abq8513
Language:
English
Publisher:
American Association for the Advancement of Science (AAAS)
Publication Date:
2023